advertisement

Home Education Educational Calendar PCA 2019

Evolving Role of the Urologist in Metastatic and Castration Resistant Prostate Cancer: a Guidelines and Case-based Discussion.

Overview/Register

Designed for residents, fellows and APPs as well as urologists and other health care providers who care for patients with prostate cancer, this interactive live forum will focus on the application of knowledge with case studies and small group discussion integrated throughout the day.

Needs assessment findings show strong support for continued development of courses and educational materials specifically targeted at residents and fellows that cover the medical management of advanced prostate cancer.

Though complimentary, pre-registration is required and space is limited.

Register Now

Maximum of 5.75 AMA PRA Category 1 CreditsTM

Presented by the AUA in partnership with the Society of Urologic Oncology (SUO). Society of Urologic Oncology

Course Co–Directors

Michael S. Cookson, MD, MMHC
David F. Jarrad, MD

Target Audience

This activity is designed for urology residents, fellows, advanced practice providers, urologists, and other healthcare providers who care for patients with prostate cancer.

Course Description

Designed for residents, fellows and APPs as well as urologists and other health care providers who care for patients with prostate cancer, this interactive live forum will focus on the application of knowledge with case studies and small group discussion integrated throughout the day. The AUA in partnership with the Society of Urologic Oncology (SUO) is proud to offer this course as complimentary to the Urology community.

Needs assessment findings show strong support for continued development of courses and educational materials specifically targeted at residents and fellows that cover the medical management of advanced prostate cancer.


Learning Objectives

At the conclusion of this activity, participants will be able to:

Practice Gap #1 (Disease State)

  1. Describe the natural course of advanced prostate cancer from non-metastatic (M0) to metastatic hormone-sensitive disease (mHSPC), with progression to the development of castration-resistant disease (CRPC).
  2. Describe the treatment options and outcomes for patients with biochemical recurrence after failed local therapy.
  3. Identify available imaging and indications for use including next generation PET imaging in the assessment of men with biochemical recurrence after failed local therapy.
  4. Describe the treatment options and outcomes for newly diagnosed mHSPC.
  5. Explain the implications of CRPC on the management of both M0 and M1.
  6. Discuss the molecular mechanisms and characterization of CRPC.
  7. Discuss the incorporation of genetic testing into the management of men with high risk, metastatic prostate cancer and CRPC.

Practice Gap #2 (Guidelines)

  1. Discuss specific recommendations within the AUA Clinical Practice Guidelines.
  2. Define M0 CRPC and the treatment options.
  3. Discuss clinically meaningful endpoints in clinical trials of patients with MO CRPC.
  4. Describe gaps in the knowledge for treatment and sequencing of agents in the management of CRPC.
  5. Discuss challenges in incorporating AUA Guidelines and management of advanced mHSPC and CRPC into community practice.

Practive Gap #3 (Androgen Axis)

  1. Identify approved androgen biosynthesis and receptor blockers for treatment of CRPC.
  2. Appraise the clinical use and efficacy of approved androgen-axis therapeutics for CRPC.
  3. Anticipate, manage and treat adverse events from therapeutic interventions directed at the androgen-axis used in the treatment of CRPC.
  4. Discuss new uses for androgen axis agents in M0 CRPC.

Practice Gap #4 (Chemotherapy, Immunotherapy, and Co-Morbidity)

  1. Identify approved chemotherapeutics and immunotherapy for mCRPC.
  2. Describe indications and contraindications for chemotherapy and immunotherapy in patients with mCRPC.
  3. Identify co-morbid states and recognize their impact on treatment options for mCRPC.
  4. Discuss treatment sequencing.

Practice Gap #5 (Bone health and Radionuclide Therapy)

  1. Integrate advances in bone health management into patient-specific care plans.
  2. Identify patients and prescribe radionuclide therapy in appropriate patients with symptomatic mCRPC.
  3. Discuss known adverse events associated with androgen biosynthesis inhibitors and radionuclide therapy.

Practice Gap #6 (Pain Management and Palliative Care)

  1. Assess and manage pain in patients with symptomatic mHSPC and mCRPC.
  2. Discuss the role of chemotherapy, performance status and pain management in patients with mCRPC.

Activity 1 – Live Forum

As the capstone to this initiative, a live, interactive forum will be held for participants to engage with subject matter expects and mentors. For convenience, the first live forum will be held the day prior to AUA Annual Meeting in Chicago.

Hotel & Transportation

Course Location

Thursday, May 2
McCormick Place
2301 S. Martin Luther King Drive
Chicago, IL 60616

Hotel Information

Chicago Live Forum

For your convenience, we recommend that live forum attendees book their stay through our official AUA2019 housing partner OnPeak. The AUA’s APP Designated Hotels are the Allegro Chicago Hotel and Hyatt Regency Chicago.

The AUA will not be providing shuttle service to the course at the Convention Center on Thursday, May 2. Shuttle service will begin on Friday, May 3, the first official day of the AUA Annual Meeting. Attendees can find transportation information and resources on the AUA2019 Website.

Registration Fees

All activities are complimentary.

Cancellation Policy

AUA Education & Research reserves the right to cancel this course if a minimum enrollment is not reached before April 1, 2019. If AUA Education & Research cancels this course, notification will be sent by April 8, 2019.

Cancellations must be made in writing. Requests may be made via mail or fax to 410-689-3912. Questions? Call 1-800-908-9414 or email registration@AUAnet.org.

Attendee Information & Policies

Disclaimer

The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the American Urological Association (AUA).

Consent to Use of Photographic Images

Registration and attendance at or participation in AUA meetings and other activities constitutes an agreement by the registrant to AUA's use and distribution (both now and in the future) of the registrant or attendee's image or voice in photographs, videotapes, electronic reproductions, and audiotapes of such events and activities.

Audio, Video, Photographic Equipment

The use of audio, video and other photographic recording equipment by attendees is prohibited inside AUA meeting rooms.

Reproduction Permission

Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the AUA.

Special Assistance/Dietary Needs

The AUA complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, please see the registration desk.

CME Information

Accreditation

The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The American Urological Association designates this live activity for a maximum of 5.75 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Other Learners

The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 CreditsTM.

Evidence Based Content

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA Disclosure Policy

All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) participating in an educational activity provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual's relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Resolution of Identified Conflict of Interest

All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point-counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
  • Divestiture of the relationship by faculty

Off-label or Unapproved Use of Drugs or Devices

The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Advertisement

Advertisement

advertisement

advertisement